NAV

Onapristone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Onapristone
DrugBank Accession Number
DB12637
Background

Onapristone has been used in trials studying the treatment of Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Androgen-independent Prostate Cancer, and Progesterone Receptor Positive Tumor: Max 1 Line of Prior Chemotherapy, no Prior Hormone Therapy.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 449.635
Monoisotopic: 449.29299412
Chemical Formula
C29H39NO3
Synonyms
  • Onapristone
External IDs
  • ZK-98299
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UGlucocorticoid receptorNot AvailableHumans
UProbable G-protein coupled receptor 133Not AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AmbroxolThe risk or severity of methemoglobinemia can be increased when Onapristone is combined with Ambroxol.
ArticaineThe risk or severity of methemoglobinemia can be increased when Onapristone is combined with Articaine.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Onapristone is combined with Benzocaine.
Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when Onapristone is combined with Benzyl alcohol.
BupivacaineThe risk or severity of methemoglobinemia can be increased when Onapristone is combined with Bupivacaine.
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as oxosteroids. These are steroid derivatives carrying a C=O group attached to steroid skeleton.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Oxosteroids
Direct Parent
Oxosteroids
Alternative Parents
3-oxosteroids / 17-hydroxysteroids / Dialkylarylamines / Aniline and substituted anilines / Cyclohexenones / Tertiary alcohols / Cyclic alcohols and derivatives / Primary alcohols / Organopnictogen compounds / Organic oxides
show 1 more
Substituents
17-hydroxysteroid / 3-oxosteroid / Alcohol / Amine / Aniline or substituted anilines / Aromatic homopolycyclic compound / Benzenoid / Carbonyl group / Cyclic alcohol / Cyclic ketone
show 17 more
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
H6H7G23O3N
CAS number
96346-61-1
InChI Key
IEXUMDBQLIVNHZ-YOUGDJEHSA-N
InChI
InChI=1S/C29H39NO3/c1-28-18-25(19-5-8-21(9-6-19)30(2)3)27-23-12-10-22(32)17-20(23)7-11-24(27)26(28)13-15-29(28,33)14-4-16-31/h5-6,8-9,17,24-26,31,33H,4,7,10-16,18H2,1-3H3/t24-,25+,26-,28+,29+/m0/s1
IUPAC Name
(10S,11S,14S,15R,17R)-17-[4-(dimethylamino)phenyl]-14-hydroxy-14-(3-hydroxypropyl)-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-1,6-dien-5-one
SMILES
CN(C)C1=CC=C(C=C1)[C@H]1C[C@]2(C)[C@@H](CC[C@]2(O)CCCO)[C@@H]2CCC3=CC(=O)CCC3=C12

References

General References
Not Available
PubChem Compound
5311505
PubChem Substance
347828846
ChemSpider
4470982
BindingDB
50366558
ChEMBL
CHEMBL1908373
ZINC
ZINC000003831947
Wikipedia
Onapristone

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentEndometrioid Endometrial Cancer / Granulosa Cell Ovarian Cancer / Low Grade Serous Ovarian/ Primary Peritoneal Cancer1
2Active Not RecruitingTreatmentRefractory Endometrial Adenocarcinoma / Refractory Endometrial Carcinoma / Refractory Endometrial Clear Cell Adenocarcinoma / Refractory Endometrial Endometrioid Adenocarcinoma / Refractory Endometrial Mixed Cell Adenocarcinoma / Refractory Endometrial Serous Adenocarcinoma / Refractory Endometrial Undifferentiated Carcinoma1
2TerminatedTreatmentEstrogen Receptor Positive Breast Cancer / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast / Metastatic Cancer1
1WithdrawnTreatmentMetastatic Breast Cancer / Unresectable Breast Cancer1
1, 2Active Not RecruitingTreatmentBreast Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00759 mg/mLALOGPS
logP4.63ALOGPS
logP3.96Chemaxon
logS-4.8ALOGPS
pKa (Strongest Acidic)14.34Chemaxon
pKa (Strongest Basic)4.89Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area60.77 Å2Chemaxon
Rotatable Bond Count5Chemaxon
Refractivity135.3 m3·mol-1Chemaxon
Polarizability52.99 Å3Chemaxon
Number of Rings5Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0w29-0000900000-f1db5d2d1af77260b0e0
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0002-0000900000-38df9f0b9b21d71bb69b
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0f8i-0429800000-727146dda69311e2d961
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0002-0000900000-f369ea2a93b7a8519c56
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-006t-0009800000-5d7d6d16315b15dd98b3
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0fl1-7439100000-1b499509f1df817a3bf0
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-231.8600349
predicted
DarkChem Lite v0.1.0
[M-H]-203.04092
predicted
DeepCCS 1.0 (2019)
[M+H]+231.5653349
predicted
DarkChem Lite v0.1.0
[M+H]+205.17628
predicted
DeepCCS 1.0 (2019)
[M+Na]+231.3625349
predicted
DarkChem Lite v0.1.0
[M+Na]+211.03996
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Glucocorticoid receptor
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Schaaf MJ, Lewis-Tuffin LJ, Cidlowski JA: Ligand-selective targeting of the glucocorticoid receptor to nuclear subdomains is associated with decreased receptor mobility. Mol Endocrinol. 2005 Jun;19(6):1501-15. Epub 2005 Feb 10. [Article]
Details2. Probable G-protein coupled receptor 133
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
G-protein coupled receptor activity
Specific Function
Orphan receptor. Signals via G(s)-alpha family of G-proteins.
Gene Name
ADGRD1
Uniprot ID
Q6QNK2
Uniprot Name
Adhesion G-protein coupled receptor D1
Molecular Weight
96529.025 Da
References
  1. Sachdeva G, Gadkar S, Shah CA, Kholkute SD, Puri CP: Characterization of a critical region in the hormone binding domain of sperm progesterone receptor. Int J Androl. 2005 Apr;28(2):120-4. [Article]

Drug created at October 20, 2016 23:22 / Updated at February 21, 2021 18:53